



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Frank et al.  
Serial No.: 08/901,612  
Filed: July 28, 1997  
Entitled: OLIGONUCLEOTIDES SPECIFIC FOR HEPATITIS B VIRUS  
Examiner: J. Epps  
Group Art Unit: 1635  
Attorney Docket No.: HYB-014US6 (1006/015)

#45/K.T.  
10/28  
Revoc.  
w/ P.D.A.

Assistant Commissioner for Patents  
Washington, DC 20231

**POWER OF ATTORNEY BY ASSIGNEE OF ENTIRE INTEREST,  
REVOCATION OF PRIOR POWERS, CHANGE OF CORRESPONDENCE  
ADDRESS, and CERTIFICATE UNDER 37 C.F.R. 3.73(b)**

Sir:

The undersigned Assignee of the above-identified United States patent application hereby revokes all powers of attorney previously created and appoints the following attorneys with full power of substitution and revocation to prosecute the application and to transact all business in the Patent and Trademark Office connected therewith:

Stacey L. Channing	Reg. No. 31,095
Wayne A. Keown, Ph.D.	Reg. No. 33,923
Robert McIsaac	Reg. No. 46,918
Susan M. Mulvaney	Reg. No. 48,269

All future correspondence should be sent to:

Keown & Associates  
500 West Cummings Park  
Suite 1200  
Woburn, MA 01801  
Telephone: 781-938-1805  
Facsimile: 781-938-4777

**RECEIVED**

OCT 11 2002

TECH CENTER 1600/2900

**CERTIFICATE UNDER 37 C.F.R. 3.73(b)**

Hybridon, Inc. a corporation existing under the laws of the State of Delaware whose address is 345 Vassar Street, Cambridge, Massachusetts 02139, certifies that it is the Assignee of the entire right, title and interest in the patent identified above by virtue of an Assignment from the inventor(s) of the patent application recorded in the United States Patent and Trademark Office on June 2, 1997 at **Reel 8543, Frame 0870**.

The undersigned has reviewed all the documents in the chain of title of the patent application identified above, and, to the best of the undersigned's knowledge and belief, title is in the Assignee identified above.

The undersigned whose title is supplied below is empowered to act on behalf of the Assignee.


The undersigned further declares that all statements made herein are of its own knowledge and are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the patent.

Respectfully submitted,

By: Robert G. Andersen

Title: Chief Financial Officer

Signature:



Date:

3 Sept '02